20P The immune profiles in young, adult and elderly of advanced stage colorectal cancer patients
ConclusionThere were significant differences in immune profile between young, adult and elderly colorectal cancer patients.Legal entity responsible for the studyThe authors.FundingHas not received any funding.DisclosureAll authors have declared no conflicts of interest. (Source: Annals of Oncology)
Source: Annals of Oncology - December 15, 2019 Category: Cancer & Oncology Source Type: research
132P Correlation between tumour infiltration lymphocyte and PDL-1 expression in laryngeal cancer and its prognostic significance: A prospective, non-interventional trial
ConclusionThere is a positive correlation between tumour infiltration lymphocytes and PDL-1 expression in laryngeal squamous carcinoma and the higher PDL-1 expression in advanced stage laryngeal cancer is associated with better OS.Legal entity responsible for the studyThe authors.FundingHas not received any funding.DisclosureAll authors have declared no conflicts of interest. (Source: Annals of Oncology)
Source: Annals of Oncology - December 15, 2019 Category: Cancer & Oncology Source Type: research
148P NKG2E comprises an immunogenic peptide, derived from an alu-retrotransposon: An attractive novel target for immunotherapeutic approaches
ConclusionNKG2E protein represents an aberrant molecule that is misexpressed in multiple cancers, including immunologically “cold” tumor types. Characterization of the rare immune cells producing the aberrant NKG2E molecule in normal tissues warrants further research. Subsequent studies could inquire into a TCD4-specific TCR usage that would allow for the inoculation of cancer patients with autologous CD4-T cells rea ctive against the Alu-peptide.Legal entity responsible for the studySpyros I. Papamichos.FundingHas not received any funding.DisclosureThe author has declared no conflicts of interest. (Source: Annals of Oncology)
Source: Annals of Oncology - December 15, 2019 Category: Cancer & Oncology Source Type: research
5P Differential expression patterns of immune checkpoint markers in tumour-stromal microenvironment of primary and chemoreduced retinoblastoma
ConclusionThis is the first of its kind study predicting a relevant role of the immune checkpoint markers in primary and chemoreduced retinoblastoma with prognostic significance. Differential expression of these markers in both group of retinoblastoma is a novel finding and might be an interesting and beneficial target for chemoresistant tumors.Legal entity responsible for the studyThe authors.FundingHas not received any funding.DisclosureAll authors have declared no conflicts of interest. (Source: Annals of Oncology)
Source: Annals of Oncology - December 15, 2019 Category: Cancer & Oncology Source Type: research
116P Development of advanced human immune system mouse models for pre-clinical research in immuno-oncology
ConclusionCollectively, the huNCG mouse model demonstrats its relevance for the preclinical testing (Mono and Combo therapies) of drugs in immuno-oncology.Legal entity responsible for the studyThe authors.FundingTranscure Bioservices.DisclosureAll authors have declared no conflicts of interest. (Source: Annals of Oncology)
Source: Annals of Oncology - December 15, 2019 Category: Cancer & Oncology Source Type: research
73P Real-world experience of immune-mediated hepatitis in Danish lung cancer patient using PD1 inhibitors
ConclusionLiver toxicity frequency correlates to findings in clinical trials (KEYNOTE-024 and KEYNOTE-042) and are mainly of grade 1. There was no correlation, in this dataset, between dose of steroids and time to normalizing of transaminases in patients treated with immunosuppressants.Legal entity responsible for the studyThe authors.FundingHas not received any funding.DisclosureAll authors have declared no conflicts of interest. (Source: Annals of Oncology)
Source: Annals of Oncology - December 15, 2019 Category: Cancer & Oncology Source Type: research
98P Results from a phase I study of MK-1308 (anti –CTLA-4) plus pembrolizumab in previously treated advanced small cell lung cancer
ConclusionIn heavily pretreated pts with SCLC, MK-1308 + pembrolizumab was generally well tolerated with encouraging antitumor activity.Clinical trial identificationNCT03179436.Editorial acknowledgementMedical writing and/or editorial assistance was provided by Holly C. Cappelli, PhD, CMPP, and Dana Francis, PhD, of the ApotheCom pembrolizumab team (Yardley, PA, USA) and funded by Merck Sharp& Dohme Corp, a subsidiary of Merck& Co., Inc., Kenilworth, NJ, USA.Legal entity responsible for the studyMerck Sharp and Dohme Corp., a subsidiary of Merck& Co., Inc., Kenilworth, NJ, USA.FundingMerck Sharp and Dohme Corp....
Source: Annals of Oncology - December 15, 2019 Category: Cancer & Oncology Source Type: research
55P Incidence and clinical implications of late immune-related adverse events in long responders to PD-1/PD-L1 checkpoint inhibitors: A multicenter study
ConclusionLate-irAEs among long responders seem to have a mild/moderate incidence. They are mostly non-serious and clinical manageable, with a low rate of treatment discontinuation. In this positive-selected population, the occurrence of any grade late-irAEs seems to be furtherly related to a prolonged OS.Legal entity responsible for the studyThe authors.FundingHas not received any funding.DisclosureAll authors have declared no conflicts of interest. (Source: Annals of Oncology)
Source: Annals of Oncology - December 15, 2019 Category: Cancer & Oncology Source Type: research
46O Impact of early introduction of steroid on immune-checkpoint inhibitors (ICI) in patients with advanced non-small cell lung cancer treated
ConclusionIntroduction of steroids within the first 8 weeks of ICI has no detrimental impact on prognosis if the indication is not related to cancer symptoms.Legal entity responsible for the studyThe authors.FundingHas not received any funding.DisclosureL. Mezquita: Advisory / Consultancy: Roche Diagnostics; Speaker Bureau / Expert testimony: Bristol-Myers; Speaker Bureau / Expert testimony: Squibb; Speaker Bureau / Expert testimony: Tecnofarma; Speaker Bureau / Expert testimony: Roche; Speaker Bureau / Expert testimony: AstraZeneca; Travel / Accommodation / Expenses: Bristol-Myers; Travel / Accommodation / Expenses: Squib...
Source: Annals of Oncology - December 15, 2019 Category: Cancer & Oncology Source Type: research
21P Prognostic biomarkers in lung cancer patients treated with immunotherapy
ConclusionIn our cohort of patients, both LIPI score and NLR are prognostic factors for overall survival in advanced lung cancer patients treated with pembrolizumab and nivolumab. Prospective studies are needed to validate the value of these biomarkers in immunotherapy.Legal entity responsible for the studyThe authors.FundingHas not received any funding.DisclosureAll authors have declared no conflicts of interest. (Source: Annals of Oncology)
Source: Annals of Oncology - December 15, 2019 Category: Cancer & Oncology Source Type: research
133P Tumour immune infiltrate characterization in luminal breast cancer in three distinct age categories and its correlation with frailty
ConclusionIn conclusion, sTILs percentage and density of several immune markers in the tumor significantly differed between young and older patients with BC. Moreover, density of regulatory T-cells was higher in frailer patients (lower G8 score). This may indicate that tumor immune responses in these patients may be less effective, and approaches for immunotherapy may vary depending on patients ’ age/frailty level.Legal entity responsible for the studyHans Wildiers.FundingFWO.DisclosureAll authors have declared no conflicts of interest. (Source: Annals of Oncology)
Source: Annals of Oncology - December 15, 2019 Category: Cancer & Oncology Source Type: research
37P Chemokine receptor CCR2b expressing anti-Tn-MUC1 CAR-T cells enhanced anti-breast cancer activity
ConclusionOur data demonstrated that the anti-tumour activity of the CCR2b expressing anti-Tn-MUC1 CART cells is 1.5 times more potent than CART cells without CCR2b. Augmentation of tumour suppression was also demonstrated in vivo in a murine xenograft model. These pre-clinical results show translational potential to the clinic for treatment of solid breast tumours.Legal entity responsible for the studyGuangzhou Anjie Biomedical Technology Co. Ltd.FundingGuangzhou Anjie Biomedical Technology Co. Ltd.DisclosureAll authors have declared no conflicts of interest. (Source: Annals of Oncology)
Source: Annals of Oncology - December 15, 2019 Category: Cancer & Oncology Source Type: research
6P Prognostic significance of tumour-infiltrating lymphocytes on survival outcomes of patients with resected pancreatic ductal adenocarcinoma: A systematic review and meta-analysis
ConclusionTILs are a promising prognostic biomarker in pancreatic cancer. High levels of CD8+ TILs correlated with favorable OS and DFS, while high levels of FoxP3+ TILs associated with poor OS. Nonetheless, results of this meta-analysis should be approached with caution due to the lack of established standards in assessment of TILs and the small number of available studies. Prospective studies that assess TILs in a more comprehensive and standardized manner are needed.Legal entity responsible for the studyThe authors.FundingHas not received any funding.DisclosureAll authors have declared no conflicts of interest. (Source: Annals of Oncology)
Source: Annals of Oncology - December 15, 2019 Category: Cancer & Oncology Source Type: research
99P A platform for extracellular interactome discovery identifies novel functional binding partners for the immune receptors B7-H3/CD276 and PVR/CD155
ConclusionHere we developed a new platform for elucidation of secreted or membrane protein interactomes. The power of this technology is demonstrated by identification of new interactors for emerging therapeutic targets such as PVR or B7-H3. These results provide insights into immune receptor biology and highlight potential new cellular targets, ultimately serving as a unique tool to inform therapeutic development.Legal entity responsible for the studyThe authors.FundingGenentech Inc.DisclosureAll authors have declared no conflicts of interest. (Source: Annals of Oncology)
Source: Annals of Oncology - December 15, 2019 Category: Cancer & Oncology Source Type: research
74P Cost of adverse events (AEs) with second-line (2L) immuno-oncology agents (IO) and chemotherapy (CHEMO) in advanced non-small cell lung cancer (aNSCLC) in the real-world
ConclusionIn this RW analysis in pts with aNSCLC, 2L IO was associated with lower costs for the management of grade 3-4 AEs than 2L CHEMO.Editorial acknowledgementWriting assistance was provided by Roland Tacke, PhD, of Evidence Scientific Solutions Inc, funded by Bristol-Myers Squibb.Legal entity responsible for the studyBristol-Myers Squibb.FundingBristol-Myers Squibb.DisclosureC.K. Wang: Shareholder / Stockholder / Stock options, Full / Part-time employment: COTA. K. Gupte-Singh: Full / Part-time employment: Bristol-Myers Squibb. A.J. Belli: Shareholder / Stockholder / Stock options, Full / Part-time employment: COTA. D...
Source: Annals of Oncology - December 15, 2019 Category: Cancer & Oncology Source Type: research
